Hemogenyx Pharmaceuticals PLC Result of Extraordinary General Meeting
09 Diciembre 2024 - 7:30AM
RNS Regulatory News
RNS Number : 3752P
Hemogenyx Pharmaceuticals PLC
09 December 2024
9 December 2024
Hemogenyx Pharmaceuticals
plc
("Hemogenyx
Pharmaceuticals" or the "Company")
Result of Extraordinary
General Meeting
Hemogenyx Pharmaceuticals plc is
pleased to announce that, at the Extraordinary General Meeting
("GM") held earlier today, all resolutions were duly passed on a
show of hands. The numbers of proxy votes for each resolution
submitted prior to the meeting are presented below.
Proxy Voting Results
|
Ordinary Resolutions
|
Votes for
|
% of votes cast for
|
Votes Against
|
% of votes cast against
|
Total votes cast
|
Total votes cast as % of
ISC (1)
|
Votes with-held (2)
|
|
1. To grant the Directors with
authority to subdivide and reclassify the existing ordinary
shares.
|
518,007,554
|
95.39
|
25,041,580
|
4.61
|
543,049,134
|
38.74%
|
1,494,053
|
|
2. To grant the Directors with
authority to consolidate the New Ordinary Shares.
|
518,772,622
|
95.41
|
24,976,512
|
4.59
|
543,749,134
|
38.79%
|
794,053
|
|
3. To grant the Directors authority
to allot and issue shares and grant rights to subscribe for shares
in the Company for the purposes of Section 551 of the
Act.
|
500,896,092
|
92.24
|
42,153,042
|
7.76
|
543,049,134
|
38.74%
|
1,494,053
|
|
Special Resolutions
|
Votes for
|
% of votes cast for
|
Votes against
|
% of votes cast against
|
Total votes cast
|
Total votes cast as % of
ISC (1)
|
Votes with-held (2)
|
|
4. To approve the adoption of the
New Articles.
|
514,762,980
|
94.80
|
28,213,641
|
5.20
|
542,976,621
|
38.73%
|
1,566,566
|
|
5. To dis-apply the statutory rights
of pre-emption in respect of the allotment of equity securities for
cash under Section 561(1) of the Act.
|
493,949,091
|
92.78
|
38,427,061
|
7.22
|
532,376,152
|
37.98%
|
12,167,035
|
(1) The
Company's issued share capital ("ISC") on 5 December 2024, being
the date on which members had to be entered in the register of
members of the Company in order to be entitled to attend and vote
at the meeting, was 1,401,815,988 ordinary shares.
(2) A 'vote
withheld' in respect of any resolution is not a vote in law and is
not counted in the calculation of the proportion of the votes for
and against it.
A copy of the resolutions passed has
been submitted to the National Storage Mechanism and will shortly
be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Enquiries:
|
Hemogenyx Pharmaceuticals plc
|
https://hemogenyx.com
|
|
Dr Vladislav Sandler, Chief
Executive Officer & Co-Founder
|
headquarters@hemogenyx.com
|
|
Peter Redmond, Director
|
peter.redmond@hemogenyx.com
|
|
|
|
|
SP
Angel Corporate Finance LLP
|
Tel: +44 (0)20 3470 0470
|
|
Matthew Johnson, Vadim Alexandre,
Adam Cowl
|
|
|
|
|
|
Peterhouse Capital Limited
|
Tel: +44 (0)20 7469 0930
|
|
Lucy Williams, Duncan Vasey, Charles
Goodfellow
|
|
About Hemogenyx
Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a
publicly traded company (LSE: HEMO) headquartered in London, with
its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and
Immugenyx LLC, located in New York City at its state-of-the-art
research facility.
The Company is a pre-clinical stage
biopharmaceutical group developing new medicines and treatments to
treat blood and autoimmune disease and to bring the curative power
of bone marrow transplantation to a greater number of patients
suffering from otherwise incurable life-threatening diseases.
Hemogenyx Pharmaceuticals is developing several distinct and
complementary product candidates, as well as platform technologies
that it uses as engines for novel product development.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
ROMEADANEAPLFFA
Hemogenyx Pharmaceuticals (LSE:HEMO)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
